- Home
- HBNC vs MLYS Comparison
HBNC vs MLYS Comparison
Compare HBNC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBNC
- MLYS
- Stock Information
- Founded
- HBNC 1873
- MLYS 2019
- Country
- HBNC United States
- MLYS United States
- Employees
- HBNC N/A
- MLYS N/A
- Industry
- HBNC Major Banks
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- HBNC Finance
- MLYS Health Care
- Exchange
- HBNC Nasdaq
- MLYS Nasdaq
- Market Cap
- HBNC 648.7M
- MLYS 590.3M
- IPO Year
- HBNC N/A
- MLYS 2023
- Fundamental
- Price
- HBNC $15.87
- MLYS $13.88
- Analyst Decision
- HBNC Hold
- MLYS Strong Buy
- Analyst Count
- HBNC 3
- MLYS 2
- Target Price
- HBNC $15.33
- MLYS $30.00
- AVG Volume (30 Days)
- HBNC 169.0K
- MLYS 131.3K
- Earning Date
- HBNC 10-23-2024
- MLYS 11-05-2024
- Dividend Yield
- HBNC 4.10%
- MLYS N/A
- EPS Growth
- HBNC N/A
- MLYS N/A
- EPS
- HBNC 0.43
- MLYS N/A
- Revenue
- HBNC $179,998,000.00
- MLYS N/A
- Revenue This Year
- HBNC N/A
- MLYS N/A
- Revenue Next Year
- HBNC $7.84
- MLYS N/A
- P/E Ratio
- HBNC $36.11
- MLYS N/A
- Revenue Growth
- HBNC N/A
- MLYS N/A
- 52 Week Low
- HBNC $9.22
- MLYS $5.85
- 52 Week High
- HBNC $16.64
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- HBNC 60.42
- MLYS 66.40
- Support Level
- HBNC $14.44
- MLYS $13.24
- Resistance Level
- HBNC $16.05
- MLYS $13.86
- Average True Range (ATR)
- HBNC 0.40
- MLYS 0.55
- MACD
- HBNC 0.11
- MLYS 0.07
- Stochastic Oscillator
- HBNC 88.82
- MLYS 89.17
About HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.